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P
arasites of the genus Plasmodium 
cause many hundreds of millions 
of cases of malaria worldwide 
every year. There is recently renewed 
optimism that in the future effective 
vaccination will join the current 
strategies of preventive and therapeutic 
uses of antimalarials, and of reduction 
in human–vector contact, as part of the 
global malaria control toolkit.
Malaria vaccine targets
The complex life cycle of the malaria 
parasite, a protozoan of the phylum 
Apicomplexa, requires a sophisticated 
array of proteins. These are encoded by 
a genome of 23 Mb distributed across 
14 chromosomes in P. falciparum [1], 
signiﬁ  cantly larger than the genome 
of any human pathogen for which 
effective vaccines have been successfully 
developed. Vaccine candidates for 
P. falciparum and P. vivax that have 
advanced to clinical trials in recent 
years are targeted against two distinct 
stages of the parasite life cycle. The ﬁ  rst 
is the sporozoite, which is injected by 
the bite of a mosquito into the human 
host as a haploid, free-living unicellular 
form, and which seeks out the liver, 
where it invades a hepatocyte and 
undergoes intracellular multiplication. 
Among key target antigens at this stage 
are thrombospondin-related adhesive 
protein (TRAP), liver-stage antigen 1 
(LSA-1) and circumsporozoite protein 
(CSP). The most successful malaria 
vaccine to date, the recombinant 
protein RTS,S administered with the 
adjuvant AS02A, afforded sustained 
protection to ~30% of children under 
ﬁ  ve years of age in a large proof-of-
principle Phase II trial in Mozambique 
[2]. This vaccine is based on the CSP 
antigen, and is designed to prevent 
infection.
A second major class of malaria 
vaccines targets the blood stage of 
the life cycle. This intraerythrocytic 
stage of infection is responsible for the 
syndrome of clinical symptoms familiar 
to us as malaria. Free-living merozoites 
in the blood, before invading a host 
erythrocyte, present the immune 
system with a number of potential 
immunogens. Among these, merozoite 
surface protein 1 (MSP-1) is considered 
one of the most promising vaccine 
targets, and a number of candidate 
MSP-1 vaccines are currently in the 
development pipeline. Many of these 
are based on the 19 kDa polypeptide 
at the carboxyl terminus of the MSP-
1 protein, MSP-119. As a prime target 
of natural immune responses in 
malaria-exposed populations, MSP-1 
is a polymorphic antigen, and many 
variants can occur in a single parasite 
population. Therefore, there is a risk 
that MSP-1 vaccine-elicited immune 
responses may be variant speciﬁ  c, and 
thus not provide protection against 
all parasite genotypes encountered 
within a given population. The MSP-119 
portion of the molecule is relatively 
conserved, but does contain six 
polymorphic amino acid residues that 
may contribute to immune evasion by 
the parasite.
Developing the Capacity 
for Malaria Vaccine Trials—
Bandiagara, Mali
Renewed interest in the testing of 
malaria vaccines at a number of clinical 
trial sites in sub-Saharan Africa has lead 
to development of the infrastructure 
and expertise required for Phase II 
and Phase III studies of vaccine safety, 
immunogenicity, and efﬁ  cacy. One 
of these sites is at Bandiagara, Mali, 
where malaria transmission is intense 
but highly seasonal. In this month’s 
PLoS Medicine, Shannon Takala 
and colleagues present a detailed 
longitudinal analysis of polymorphisms 
in the msp-1 genes of parasite isolates 
taken from a cohort of a broad age 
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Glossary
CSP: Circumsporozoite protein, a 
candidate sporozoite vaccine antigen; 
primary component of the RTS,S vaccine
Haplotype: Literally a “haploid 
genotype.” As used in this article, refers 
to a particular combination of linked 
polymorphisms occurring in a particular 
parasite clone
LSA-1: Liver-stage antigen 1; candidate 
liver-stage vaccine antigen
Merozoite: Free-living parasite that 
emerges from infected hepatocytes and 
invades erythrocytes to initiate disease-
causing blood-stage malaria; replication 
in erythrocytes releases further 
merozoites every 48–72 hours
MSP-1: Merozoite surface protein 1; a 
large multi-domain protein associated 
with the merozoite apical complex; 
cleaved by speciﬁ  c proteases during 
erythrocyte invasion
MSP-119: Carboxyl-terminal domain 
of MSP-1 retained on the merozoite 
surface after proteolytic cleavage; quite 
conserved in sequence, and shown to 
elicit protective immune responses in a 
number of studies; a leading candidate 
blood-stage antigen
Sporozoite: Free-living malaria parasite 
stage injected into vertebrate host by 
mosquito bite; invades hepatocytes
TRAP: Thrombospondin-related adhesive 
protein, a candidate sporozoite/liver 
stage vaccine antigenPLoS Medicine  |  www.plosmedicine.org 0414
range in Bandiagara [3]. Monthly 
peripheral blood samples (n = 2,309) 
from a random selection of 100 cohort 
participants across three age strata 
were analysed through three malaria 
transmission seasons from 1999 to 
2001. This group of 100 individuals 
provided a staggering 1,375 parasite-
positive events during this time, and 
these isolates were analysed for msp-1 
polymorphisms by pyrosequencing. 
The authors use the data to present 
an analysis of the population-level 
dynamics of 14 different haplotypes 
encoding MSP-119. The study provides 
novel and important information on 
three levels. 
First, Takkala and colleagues are 
able to measure the prevalence of 
different MSP-119 haplotypes in the 
population and demonstrate dynamic 
ﬂ  uctuations over the three-year 
study. These data can inform vaccine 
design, by indicating that either of 
two dominant haplotypes (QKSNGL 
and EKSNGL, respectively, at the six 
polymorphic amino acid positions) 
occur in about 80% of infections 
overall. In contrast, the haplotype 
ETSSRL, found in the 3D7 laboratory 
clone of P. falciparum, and the basis 
of one leading MSP-1 vaccine, FMP1/
AS02A, occurred in only 16% of 
infections. Thus, if vaccine-elicited 
anti-MSP-119 immunity is sequence 
speciﬁ  c, a vaccine targeting either 
or both of the more prevalent 
haplotypes might be more effective 
in this population. Interestingly, 
the 3D7 haplotype ETSSRL, and 
two other haplotypes, appeared to 
be signiﬁ  cantly more common in 
asymptomatic infections, a result 
largely accounted for in multivariate 
modelling by an association with 
lower parasite densities. This raises 
the intriguing possibility that speciﬁ  c 
MSP-119 haplotypes may contribute to 
reduced virulence, but as Takkala et 
al. point out, this possibility requires 
further investigation in other endemic 
areas, and with a broader genome-wide 
analysis of parasite polymorphism.
Second, it was found that the 
seasonality of malaria transmission 
in Mali has a profound effect on the 
prevalence of some MSP-119 haplotypes, 
on the average number of parasite 
clones in each infection, and on the 
relative proportion of parasite-positive 
individuals who had symptomatic 
malaria, as opposed to asymptomatic 
infection, in each age group. Such 
“baseline” knowledge of parasite 
population dynamics, collected in 
the absence of a vaccine intervention, 
is crucial to any future analysis of 
postintervention data.
Third, careful analyses of sequential 
isolates collected from individual 
patients provide new evidence that 
some MSP-119 haplotypes elicit 
sequence-speciﬁ  c immunity. For a 
given surveillance interval in which 
two infections occurred in the same 
patient, infection with a haplotype 
differing in amino acid sequence 
at residue 1691, 1700, or 1716 was 
signiﬁ  cantly associated with risk of 
clinical malaria in the latter episode. 
This ﬁ  nding suggests that there is some 
level of haplotype-speciﬁ  c immunity, 
and may also mean that only a subset 
of the possible MSP-119 sequence 
combinations needs to be covered 
by a vaccine in order to counteract 
the effect of polymorphism at these 
residues.
Gathering Intelligence
The data presented by Takkala 
et al., gathered in the absence of 
any intervention with a vaccine, 
demonstrate the potential impact that 
parasite population diversity could have 
on the outcome of MSP-119 vaccine 
trials. Conﬁ  rmation in other endemic 
settings is required to verify the 
evidence that certain residues in this 
antigen may be particularly important 
in eliciting sequence-speciﬁ  c protection, 
and that particular haplotypes are 
associated with lower parasite densities. 
Nevertheless, this study provides ample 
warning that analysis of antigen diversity 
in the target parasite population 
should not only be gathered as part of 
postintervention evaluation in vaccine 
trials [4], but should be part of the 
intelligence gathering undertaken 
when planning intervention studies in 
the ﬁ  rst place.  
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